A new model used to predict the outcomes of pathogen detection systems as a function of innate immunity may lead to more effective cancer immunotherapies and vaccines against existing and novel pathogens, according to results published in Cell Systems on October 27. Discuss
An engineered antibody fragment has been developed as a highly potent neutralizer of SARS-CoV-2. For the first time, one of these tiny molecules has been tested for efficacy in in vitro and in vivo infection models. The results of the collaborative study were published in Cell on September 14. Discuss
A new approach to increasing the effectiveness of current cancer immunotherapies combines existing therapies with new monoclonal antibodies (mAb) that block inhibitory cytokines in tumor microenvironments, allowing the body to effectively eliminate tumors. The results of the study were published in Nature Communications on September 11. Discuss
Adjuvants are often added to vaccines as a method for promoting an immune response in recipients. But what happens when that immune response goes haywire, causing too much inflammation? Researchers believe that adding an "immune potentiator" to adjuvants that strengthens the immune reaction and modulates excess inflammation could lead to vaccines that are better tolerated in humans, according to a September 9 article in Science Advances. Discuss
Researchers have developed a CRISPR-based system that can simultaneously provide transcriptional control and gene editing on demand to improve the efficacy of gene therapies. The details were published in Nature Cell Biology on September 3. Discuss
Human genetic variation may alter the interactions of drugs being used to treat patients with COVID-19 symptoms, resulting in a range of clinical responses -- from no effect to high toxicity in some patients, according to a study published in Nature Genomic Medicine on August 18. Discuss
Rare stem cells that give rise to neutrophils in human bone marrow could offer a path to developing treatments for diseases that involve the white blood cells, according to a new article published in Immunity on August 18. Discuss
A microbe-based therapeutics platform that has been in development for nearly 30 years is gaining traction for the treatment of inflammatory and autoimmune diseases. The company that is developing the platform, Precigen ActoBio, is advancing a lead candidate through clinical trials with the long-term goal of finding a sweet spot between biologics and gene therapies. Discuss
The American Association for Cancer Research (AACR) annual meeting in virtual format featured a broad array of sessions, discussing many aspects of cancer research from drug development to treatment and patient advocacy. Discuss
A SARS-CoV-2 variant carrying an amino acid change, D614G, in the spike protein has become the predominant form of the virus in the current global pandemic. A recent publication in Cell advocated for viral surveillance to aid in the development of immunological interventions. Discuss
Conferences
2020 AACC Annual Scientific Meeting & Clinical Lab Expo
December 13-17
Online
December 13-17
Online
Society for Laboratory Automation and Screening (SLAS) 2021
January 23-27, 2021
Online
January 23-27, 2021
Online
Festival of Genomics & Biodata
January 28-29, 2021
London, Greater London United Kingdom
January 28-29, 2021
London, Greater London United Kingdom
4th Annual Cell & Gene Therapy Innovation Leaders Summit 2021 Visualising The Future
February 1-3, 2021
Berlin, Berlin Germany
February 1-3, 2021
Berlin, Berlin Germany
Lab of the Future USA
May 11-12, 2021
Boston, Massachusetts United States
May 11-12, 2021
Boston, Massachusetts United States
Science Briefs
Insights
Exclusive content for Science Advisory Board members on trends and outcomes that are influencing the future of scientific research.
Communities
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Rewards
Earn points for contributing to research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Connect
